Robotics and AI combine for new therapeutics discovery

Latest articles

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Humanpeople raising £700k for AI preventative health platform

Digital preventative health platform combines blood, DNA and microbiome testing to power up your healthspan with highly personalised supplements. DISCLOSURE: Longevity.Technology (a brand of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Click the globe for translations.

Insilico Medicine and Arctoris announce robotics/AI partnership to focus on COVID-19 inhibitors that could have wide-reaching benefits for Longevity.

Two companies have joined forces in the battle against COVID-19, planning to combine their strengths to discover and validate novel molecules more quickly.

Longevity.Technology: The pandemic is accelerating research as science races to find a way to halt the spread and effects of COVID-19. Using AI to crunch the numbers for target identification and generative chemistry for drug discovery is important, but what happens when a target is acquired?

This partnership demonstraes that rapid generation of high-quality cell-based, molecular and biochemical data is also needed to ensure speedy discovery and validation of new – and possibly game-changing – molecules.

Insilico Medicine, a biotechnology company developing an end-to-end drug discovery pipeline utilising next-gen AI, is already at the forefront of COVID-19 research; it is developing microbiomic tools, and will be releasing COVIDOMIC, a tool for exploring variables with an effect on the COVID-19 infection outcome, including those derived from patients’ respiratory microbiome.

Arctoris boasts the world’s first fully automated drug discovery platform, which offers remotely accessible, pre-optimised and fully validated R&D processes for its partners and clients globally.

The two companies have previously partnered together on BioTarget, a collaborative effort supported by Cancer Research UK that works to find new molecules for cancer treatment from partners globally, crowdsourcing the drug discovery process and making leading experimental tools accessible to researchers worldwide.


 

Democratising the drug discovery ecosystem will be beneficial for Longevity, especially as researchers work to overcome the obstacles of polypharmcy that beset an aging population.

 


 

Insilico and Arctoris will be using state-of-the-art techniques to discover, synthesise, and profile a set of inhibitors for COVID-19 treatment. Insilico identified novel small molecules using its AI capabilities, with Arctoris evaluating the intended biological actions on its robotic platform. In a develop-test-refine loop, the partners were able to iterate new molecules several times faster than the industry standard, which bodes well for new drug discovery successes. The JAK inhibitor study profiled a set of potent inhibitors that can help patients by modulating the life-threatening cytokine storm caused by COVID-19.

“We are excited to announce our technology partnership with Insilico Medicine … We see tremendous value in combining our next-generation robotic platform with Insilico’s unique capabilities in drug design. During the COVID-19 pandemic, time is of the essence, and this project demonstrates that together, we are able to accelerate the drug discovery process, and create and progress new drug candidates faster and cheaper,” said Martin-Immanuel Bittner MD DPhil, Co-Founder & CEO of Arctoris.

“Arctoris developed an advanced robotics platform that can be used for a very broad spectrum of applications in drug discovery and biological data generation. We discussed the collaboration for quite some time but this pandemic really highlighted the benefits of a close AI- and robotics-powered discovery integration,” said Alex Zhavoronkov PhD, founder, and CEO of Insilico Medicine.

Further collaboration will focus on joint drug discovery projects in oncology, a field of particular interest to both Arctoris and Insilico, with their mission to eliminate age-related disease and promote healthy Longevity.

Photo credits: Insilico and Arctoris
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Humanpeople raising £700k for AI preventative health platform

Digital preventative health platform combines blood, DNA and microbiome testing to power up your healthspan with highly personalised supplements. DISCLOSURE: Longevity.Technology (a brand of...

Printers that can now print DNA

DNA Script obtains CE Mark for SYNTAX DNA printing platform. DNA Script, a leader in Enzymatic DNA Synthesis (EDS), announced the CE marking of its SYNTAX System, the...

A brain fitbit that can spot Alzheimer’s with up to 94% accuracy

Altoida raising new financing for augmented reality cognitive assessment platform that dramatically improves early detection of Alzheimer’s and other neurodegenerative diseases. Earlier this year, AR-powered...

Insilico starts human trial with AI-discovered drug

First human dosed with AI-discovered novel molecule based on an AI-discovered novel target. Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, has announced that the...

    Subscribe to our newsletter